Analyst Price Target is $4.13
▲ +3,173.81% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Exicure in the last 3 months. The average price target is $4.13, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 3,173.81% upside from the last price of $0.13.
Current Consensus is
The current consensus among 2 polled investment analysts is to buy stock in Exicure. This Buy consensus rating has held steady for over two years.
Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.